INTRODUTION
Percutaneous CT-guided fine needle aspiration (FNA) of a lung lesion is a routinely used, relatively safe method for diagnosis of benign and malignant processes (1) . The diagnostic accuracy of CT-guided FNA for malignant lung tumors varies between 64% and 97% (2), depending on factors such as the size and depth of the lesion as well as the number of needle paths (1, 2) . FDG imaging provides information with respect to the metabolic characteristics of lung lesions (3) . Its inherent advantages include the early detection of malignancy and differentiation from non-malignant areas within a mass representing fibrosis and necrotic tissue (3) (4) (5) . FDG-PET/CT has a high sensitivity of approximately 90% in characterizing solitary pulmonary nodules but its specificity is hampered by FDG accumulation by various non-malignant processes (6, 7) . CT used for guiding of FNA does not provide information regarding the metabolic characteristics of the lesion, in particular the specific location of functionally active cells within the tumor (8) . Tissue aspiration guided only by anatomical data can therefore lead to placement of the needle into a nonviable area of the lesion with subsequent inadequate tissue sampling and potentially false negative (FN) FNA results (8, 9) .
The success rate of image-guided biopsies could be improved and multiple attempts at biopsy avoided if the functional information obtained from the FDG-PET/CT study is used to direct the positioning of the tip of the needle to the region with the highest metabolism within a lesion (9) . The purpose of this study was to demonstrate that FDG-PET/CT can provide the additional information that will decrease the false negative rate and improve the accuracy of CT-guided FNA of lung lesions. 
MATERIALS AND METHODS

Study Population
The institutional FDG-PET/CT and CT-guided biopsy databases between the years 2007 to 2010 were retrospectively searched for patients who underwent whole-body FDG-PET/CT for characterization of pulmonary nodules and CT-guided FNA of the lung lesion within a time interval of less than 30 days. Data of 311 consecutive patients who met the above criteria were retrieved. After identification of the specific patient population, data regarding cytology results of samples obtained at CT-guided FNA and histology of the same lesions obtained at surgery, when performed, as well as clinical and imaging follow-up were retrieved from their medical records. The institutional review board approved this retrospective study and the requirement to obtain informed consent was waived.
CT-Guided FNA Procedure
CT-guided FNA was performed as a non-enhanced CT procedure (Philips MX 8000 4 slices or Philips IDT 16 slices) by senior radiologists with experience ranging between 9 and 20 years. A 22-gauge needle, 9 cm or 15 cm in length, was used. A cytologist was present to evaluate the initial aspiration and to prepare the slides. Cytology results were Figures 1 and 2) . The results of FNA obtained in present study population, based only on CTguided aspiration, showed sensitivity, specificity and accuracy of 84%, 91% and 85% respectively, for diagnosis of pulmonary malignancy, similar to previously reported literature data (2, 10). However, this study aimed to examine whether combining CTguided FNA and FDG-PET/CT data had an added value in order to improve the tissue sampling accuracy. Present results demonstrate that the distance between the aspirating needle`s tip location and the area with the highest metabolic activity within the lesion was significantly greater in patients with FN as compared to those with TP FNA results. In addition, SUVmax in the location of the aspirating needle`s tip was significantly higher in the TP as compared to the FN group. These results demonstrate the relationship between the degree of metabolism at the site of aspiration within lung lesions and the accuracy of FNA results. Interestingly, there were no significant differences in lesion size and tissue heterogeneity between the TP and the FN groups. This is in contrast to the accepted assumptions that the larger and more heterogeneous the lesion is, the higher the probability for sampling error, and, that a lower FNA accuracy is expected in small lesions, mainly due to the partial volume effect (11, 12) . This lack of heterogeneity differences between the TP and FN groups further emphasis the need for quantitative measurements as a tool for more accurate tissue sampling in addition to the visual analysis of the assessed lesion.
Previous studies have examined the value of PET-guided biopsy in malignant lesions in the bone. In a retrospective study FDG-PET-directed skeletal biopsies resulted a higher number of TP and a lower number of FP biopsies as compared to sampling directed by bone scintigraphy (13) . In a case report of a patient with medullar and trabecular bone metastases, only the use of FDG-PET/CT allowed to localize the area for biopsy that produced a conclusive tissue specimen containing viable tumor while CT, MRI and bone scintigraphy failed to reliably detect bone marrow infiltration (14) .
Present study provides support for the use of FDG-PET/CT to improve the diagnostic accuracy of FNA in lung lesions. In addition to guiding the operator to the most metabolically active area of a neoplasm, there are additional advantages to the use of FDG-PET/CT to guide FNA. The use of PET/CT allows identifying the most easily accessible lesion, thereby reducing the potential need for repeat invasive procedures and the risk of complications. PET/CT can assist in guiding the operator to the metabolically active region in a lesion that is hard to locate, such as anatomical alterations after surgery or radiation therapy, or to lesions that have only minimal morphological changes on diagnostic CT. Because FDG-PET/CT can detect malignancy before significant morphological changes occur, the use of this test to guided biopsy could also contribute to providing an earlier histologic diagnosis of small tumor load malignancies.
While FDG-PET/CT is used for diagnosis and staging of lung malignances, some metabolically active benign processes can, as well, show high FDG uptake (7, (15) (16) (17) .
Differentiating inflammatory and infectious processes of benign tumors from malignancy may be difficult but confidence that the aspirating needle has been placed in the right location, higher if FNA is guided by FDG imaging is important in these cases as well.
Although there is increasing evidence to support a role for FDG-PET/CT to guide biopsies, the logistics of integrating this imaging modality into routine clinical FNA procedures is more complex. Recent reports have presented potential solutions.
Previously acquired FDG-PET/CT images have been digitally registered with the intraprocedural CT images to guide needle placement during biopsy of abdominal masses (18) . An additional study also used co-registered, previously acquired FDG-PET/CT images with intra-procedural CT images and reported that in approximately 50% of biopsies performed in various organs, the availability of metabolic information was beneficial and improved the diagnostic accuracy as compared to CT-only guided biopsy The routine clinical use of real time PET/CT guided FNA is currently limited, in part, by the fact that PET imaging for FNA procedures may require a relatively long machine time and, additionally, ionizing radiation fields close to the patient can be substantial for several hours after radiopharmaceutical injection, with potentially higher radiation exposure of the personnel performing the procedure. The development of PET scanners with higher sensitivity could shorten scan times thus increasing scanner availability and also require less radioactivity that needs to be administered. In the method proposed in the current study, since the diagnostic PET/CT acquisition is registered with the FNA CT, these limitations do not necessarily apply. In an optimal setting it would require just a suitable workstation and easy-to-use software located in the procedure room.
CONCLUSION
Present study supports the concept that anatomo-metabolic guidance of FNA (using information provided by both FDG-PET and CT) may improve the accuracy of tissue sampling, decrease the incidence of false negative results and thus may increase the probability of achieving a definitive diagnosis. Future work should focus on defining the technique and protocol to enable the clinical application of PET/CT to image-guided biopsy. 
